Can telmisartan be given in ckd stage 5 on hemodialysis
Reading File
Finding Sources
Finding Sources
Searching PubMed
telmisartan hemodialysis CKD
Finding Sources
Finding Sources
Searching PubMed
telmisartan dialysis end stage renal disease
Reading File
Finding Sources
Searching the Web
telmisartan CKD stage 5 hemodialysis safety use dose recommendation
I now have comprehensive information. Here is the full clinical answer:
Telmisartan in CKD Stage 5 on Hemodialysis
Short Answer: Yes, it can be used - with important caveats.
Telmisartan is not contraindicated in CKD stage 5 (ESRD) patients on hemodialysis, but there are several pharmacokinetic and clinical considerations that guide its use.
Pharmacokinetics in Dialysis Patients
Telmisartan has a distinctive PK profile in renal disease:
- Primarily hepatic (biliary) elimination - it is NOT renally cleared. This is why no dose adjustment is required for renal impairment, including ESRD.
- Markedly reduced plasma levels are paradoxically observed in hemodialysis patients compared with patients who have moderate-severe CKD not on dialysis. This is thought to be due to altered volume of distribution and protein binding changes.
- Not removed by hemodialysis - telmisartan is highly bound to plasma proteins in renally insufficient patients and cannot be dialyzed out. This means a missed dose cannot be "replaced" by dialysis clearance, and toxicity cannot be cleared by a dialysis session. (FDA Micardis label)
- The EMA product information confirms: "lower plasma concentrations were observed in patients with renal insufficiency undergoing dialysis. Telmisartan is highly bound to plasma protein in renal-insufficient patients and cannot be removed by dialysis."
Dosing Recommendation
- No initial dose adjustment required for ESRD/hemodialysis patients.
- Standard dosing: 40-80 mg once daily for hypertension; 80 mg once daily for cardiovascular risk reduction (ONTARGET indication).
- The Canadian prescribing information (APO-Telmisartan) explicitly states: "No initial dosing adjustment is necessary for patients with renal impairment, but greater sensitivity in some older individuals cannot be ruled out."
Key Clinical Concerns in Hemodialysis Patients
| Concern | Details |
|---|---|
| Orthostatic hypotension | Patients on dialysis may develop orthostatic/intradialytic hypotension - blood pressure must be closely monitored |
| Hyperkalemia | ARBs block aldosterone, reducing potassium excretion. In anuric/oliguric ESRD patients, potassium removal depends almost entirely on dialysis - risk of life-threatening hyperkalemia is real |
| Hypotension | Volume shifts during dialysis sessions can cause significant BP drops; telmisartan's long half-life (~24h) means its hypotensive effect persists through dialysis |
| Dual RAAS blockade | Combining with ACE inhibitor is NOT recommended (no benefit, more harm - especially hyperkalemia and AKI risk) |
| Bilateral renal artery stenosis | Contraindicated (though largely theoretical in ESRD on HD) |
| Pregnancy | Absolutely contraindicated - causes fetal renal dysgenesis |
Why Use It at All in ESRD/HD?
Indications that may justify use in dialysis patients:
- Residual proteinuria management - ARBs slow residual nephron loss and reduce proteinuria even in dialysis patients with residual renal function (important as residual function improves survival on HD).
- Hypertension control - interdialytic hypertension is common and associated with increased cardiovascular mortality; ARBs are a reasonable choice.
- Cardiovascular risk reduction - dialysis patients have very high CV mortality; ARBs have pleiotropic cardioprotective effects.
- LVH regression - ARBs are useful for left ventricular hypertrophy, which is almost universal in ESRD.
The Braunwald's Heart Disease textbook notes that ARBs (including telmisartan) are "indicated for treatment of hypertension, to reduce the progression of type 2 diabetic nephropathy" and are appropriate in CKD with cardiovascular disease.
Practical Monitoring
- Check serum potassium regularly (pre-dialysis K+ is the most relevant timepoint)
- Monitor BP pre-, intra-, and post-dialysis
- Consider timing of dose: some clinicians prefer giving the dose after dialysis to minimize intradialytic hypotension
- Monitor for angioedema (though less common with ARBs than ACEIs)
Summary
| Question | Answer |
|---|---|
| Is telmisartan contraindicated in HD? | No |
| Does it require dose adjustment for HD? | No |
| Is it removed by dialysis? | No (highly protein-bound) |
| Main risks? | Hyperkalemia, orthostatic/intradialytic hypotension |
| Can it be used with ACEi in HD? | Not recommended |
In clinical practice, telmisartan is a reasonable ARB choice for hypertensive HD patients - its hepatic metabolism makes it predictable, its long half-life gives smooth BP control, and it does not require any renal dose adjustment. The main vigilance required is for hyperkalemia and hemodynamic instability during dialysis sessions.
What about, maddreys , discriminant s- score? Um... Uh, is it applicable, um, to, uh... Mm. Uh, point of 11.2. Um, uh, can you help me, um, calculate the maddreys discriminant function?
Asking for Preferences
Asking for Preferences
Pt 15.2, pt control 13.2, total bilirubin 2.5
Maddrey's Discriminant Function Calculation
Formula: MDF = 4.6 × (PT patient − PT control) + serum bilirubin (mg/dL)
Your Values
| Parameter | Value |
|---|---|
| PT patient | 15.2 seconds |
| PT control | 13.2 seconds |
| PT prolongation | 15.2 − 13.2 = 2.0 seconds |
| Total bilirubin | 2.5 mg/dL |
Calculation
MDF = 4.6 × 2.0 + 2.5
MDF = 9.2 + 2.5
MDF = 11.7
Interpretation
| MDF Score | Interpretation |
|---|---|
| < 32 | Mild-moderate disease - conservative management, no immediate steroid indication |
| ≥ 32 | Severe alcoholic hepatitis - consider corticosteroids (prednisolone 40 mg/day × 28 days) if no contraindications |
Your patient's MDF = 11.7 - this is well below the threshold of 32, indicating mild-to-moderate alcoholic hepatitis at this time.
- Steroids are not indicated based on this score alone.
- 28-day mortality in this range is relatively low (~10-15% vs ~35-45% when MDF ≥ 32).
Important Notes
- MDF ≥ 32 is the classic cut-off for severe disease and is the threshold used in most steroid trials (Maddrey et al., 1978).
- MDF should ideally be used alongside other scores like MELD and Lille score (at day 7 of steroids) for complete risk stratification.
- A single MDF is a snapshot - if the clinical picture is deteriorating (worsening jaundice, encephalopathy), repeat the score and reassess.
- MDF does not account for encephalopathy - the Glasgow Alcoholic Hepatitis Score (GAHS) and MELD may capture this better.
This is a shared conversation. Sign in to Orris to start your own chat.